# DNL126 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dnl126

> The next catalyst for DNL126, sponsored by Denali Therapeutics Inc. (DNLI), is its NDA/BLA submission, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for DNL126?

The next catalyst for DNL126, sponsored by Denali Therapeutics Inc. (DNLI), is its NDA/BLA submission, 2027. Press release filed with the SEC (EX-99): "64 Study Data for the DNL126 Accelerated Approval BLA - Biologics licensing application; AA - Accelerated approval; CSF - Cerebrospinal fluid; HS - Heparan sulfate Expected BLA submission and approval in 2027 Data for BLA Submission" [Calendar and source filings](https://sec-api.dev/pdufa/dnl126)

Source: Press release filed with the SEC (EX-99), accession 0001714899-25-000209, https://www.sec.gov/Archives/edgar/data/1714899/000171489925000209/a20251204-denaliinvestor.htm (retrieved 2026-11-12). Last confirmed 2025-12-04. Cite: https://sec-api.dev/pdufa/dnl126#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | DNL126 |
| Codes | DNL126 |
| Sponsor | Denali Therapeutics Inc. (DNLI) https://sec-api.dev/companies/dnli/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | fast track |

## Timeline

### Feb 2024: trial start

- Status: completed. Date confidence: month. Stage: 1/2.
- First seen 2025-02-27, last confirmed 2025-02-27.
- SEC Form 10-K (accession 0001714899-25-000066): "◦In February 2024, we announced that dosing had been initiated in the Phase 1/2 study of DNL126 in MPS IIIA." https://www.sec.gov/Archives/edgar/data/1714899/000171489925000066/dnli-20241231.htm

### 2027: NDA/BLA submission

- Status: scheduled. Date confidence: year.
- First seen 2025-12-04, last confirmed 2025-12-04.
- Press release filed with the SEC (EX-99) (accession 0001714899-25-000209): "64 Study Data for the DNL126 Accelerated Approval BLA - Biologics licensing application; AA - Accelerated approval; CSF - Cerebrospinal fluid; HS - Heparan sulfate Expected BLA submission and approval in 2027 Data for BLA Submission" https://www.sec.gov/Archives/edgar/data/1714899/000171489925000209/a20251204-denaliinvestor.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dnl126.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DNL126 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dnl126

```bibtex
@misc{secapidev_pdufa_dnl126_20261116,
  title        = {DNL126 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dnl126}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dnl126_20261116","title":"DNL126 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dnl126","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
